Thermo Fisher Scientific has reached an agreement to purchase Olink Holding for an estimated USD3.1 billion, as jointly announced by the two companies. This transaction is designed to enhance the buyer's footprint in the field of proteomics.

United States:  In a significant development in the field of life sciences and diagnostics, Thermo Fisher Scientific, a global leader in serving science, has announced its intention to acquire Olink Holding AB for a staggering USD3.1 billion. The deal, which is subject to customary closing conditions and regulatory approvals, is expected to bolster Thermo Fisher's position in the rapidly growing proteomics and biomarker discovery market.

Olink, a Swedish biotechnology company, specializes in developing innovative solutions for proteomics research and diagnostics. Their state-of-the-art technology, known as proximity extension assay (PEA), enables researchers to study a wide range of proteins simultaneously with high sensitivity and accuracy. This acquisition is poised to advance Thermo Fisher's capabilities in the life sciences sector and provide a comprehensive suite of solutions for researchers, clinicians, and pharmaceutical companies.

According to the Chairman, President, and CEO of Thermo Fisher Scientific, “The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine,” he stated. “Olink’s proven and transformative innovation is highly complementary to our leading mass spectrometry and life sciences platforms.”

Olink, founded in 2004, has made a name for itself by enabling researchers to analyze proteins in blood samples for biomarker discovery and diagnostic purposes. Their innovative approach has led to numerous collaborations with pharmaceutical and biotech companies, as well as academic research institutions. Olink's technology is expected to synergize well with Thermo Fisher's existing portfolio, which includes a wide range of laboratory instruments, reagents, consumables, and software used in scientific research and healthcare.

According to the CEO of Olink, “Thermo Fisher’s deep life sciences expertise, global reach and proven operational excellence will enable significant opportunities for both customers and colleagues, while also providing immediate value to our shareholders.”

The USD3.1 billion acquisition is expected to be completed in the first half of 2024, pending customary regulatory approvals and closing conditions. The move is part of Thermo Fisher's ongoing commitment to investing in cutting-edge technologies that have the potential to drive advancements in science and healthcare.

This acquisition positions Thermo Fisher Scientific at the forefront of proteomics research and diagnostic solutions, reinforcing the company's commitment to fostering scientific progress and innovation in the field of life sciences.

As the deal progresses, both Thermo Fisher and Olink will be working together to ensure a smooth transition, integrating Olink's innovative technologies into the broader Thermo Fisher ecosystem. This development is poised to have a significant impact on the global life sciences and diagnostics landscape and pave the way for new breakthroughs in medical research and precision medicine.

According to TechSci Research, the acquisition of Olink Holding AB by Thermo Fisher Scientific Inc will be a huge asset to the healthcare industry. Olink likely possesses specialized technology and expertise in proteomics, including proprietary methods for protein analysis and biomarker discovery. The acquisition would grant Thermo Fisher access to these advanced technologies and know-how, potentially improving its proteomics capabilities. Thermo Fisher may also expand its portfolio of proteomics solutions by incorporating Olink's products, services, and assays. This would enable Thermo Fisher to offer more comprehensive and integrated solutions to its customers in the life sciences and research communities. Most importantly, the acquisition of Olink may strengthen Thermo Fisher's position in the proteomics and biomarker discovery markets. Thermo Fisher could gain a competitive edge and an increased share of the growing proteomics industry. Moreover, the integration of Olink's proteomic technologies and solutions may accelerate Thermo Fisher's research and development efforts in proteomics. This can lead to faster innovation and the development of new products and services.